LDV peptidomimetics equipped with biotinylated spacer-arms: synthesis and biological evaluation on CCRF-CEM cell line

  • Bioorg Med Chem Lett. 2012 Jan 1;22(1):586-90. doi: 10.1016/j.bmcl.2011.10.078.
Estelle Gérard  1 ,  Aline Meulle ,  Olivier Feron ,  Jacqueline Marchand-Brynaert
Affiliations
  • 1. Université catholique de Louvain (UCL), Institut de la Matière Condensée et des Nanosciences, Bâtiment Lavoisier, Place L. Pasteur, L4.01.02, B-1348 Louvain-la-Neuve, Belgium.
PMID: 22101134 DOI: 10.1016/j.bmcl.2011.10.078
Abstract

The tripeptide Leu-Asp-Val (LDV) is known to bind α(4)β(1) Integrin in leukemia cells. Here we have synthesized a LDV peptidomimetic equipped with a biotin-conjugated spacer-arm. Compound 9 acts as an inhibitor of the α(4)β(1) Integrin in an adhesion assay using fluorescently labeled, α(4)β(1) integrin-expressing leukemia CCRF-CEM cells. Furthermore, when bound to neutravidin-coated plates, compound 9 could capture CCRF-CEM cells. Such biotin-conjugated LDV peptidomimetic may thus represent a novel tool for biotechnological applications using avidin interaction for leukapheresis or leukemia cell targeting.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P2267
    LDV
    99.97%, α4β1 IntegrinLigand
    target: Integrin
    Research Areas: Others